If the cell therapy industry were a housing project, then arguably it would be at the construction stage – deciding what materials are needed to make a safe and durable product. Manufacture is a key issue for the industry, but one that is just now being confronted, according to participants at a meeting of the Alliance for Regenerative Medicine that took place in London on 3 November.
